<DOC>
	<DOCNO>NCT02724436</DOCNO>
	<brief_summary>Hepatocellular carcinoma ( HCC ) fifth most-common cancer worldwide second most-common cause cancer mortality . Liver resection first-line curative treatment huge HCC . The 5-year overall survival ( OS ) rate hepatic resection range 25 % 45 % . Transarterial chemoembolization ( TACE ) major treatment option unresectable primary secondary liver malignancy . Yittrium-90 ( Y-90 ) pure beta-emitter , without toxic effect immune rejection . There ample data support use Y-90 microspheres primary metastatic liver tumor . The aim study compare clinical outcome radioembolization Y-90 TACE provide new strategy treatment intermediate advance hepatocellular carcinoma portal vein thrombus conduting randomize trial .</brief_summary>
	<brief_title>Radioembolization With Yittrium-90 Intermediate Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . ChildPugh class A B liver function ; 2 . Preoperative ECOG criterion score 02 ; 3 . Patients preoperatively diagnose hepatocellular carcinoma accord chest compute tomography ( CT ) and/or magnetic resonance imaging ( MRI ) ; 4 . Tumor number ≤5 sum largests tumor diameter ≤15 cm ; 5 . The expected survival time &gt; 6 month . 1 . Other anticancer treatment treatment 2 . Patients apparent major organ ( i.e . cardiac , pulmonary , cerebral renal ) dysfunction , may affect treatment liver cancer 3 . Patients disease may affect treatment treatment 4 . History malignant tumor 5 . Patients participate clinical trial 6 . Pregnant , lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Yittrium-90</keyword>
	<keyword>Hepatocellular Carcinoma</keyword>
</DOC>